VYNE Therapeutics (VYNE) Institutional Ownership $0.67 -0.01 (-0.87%) As of 04:00 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Institutional Ownership Changes (13F Filings) for VYNE Therapeutics (NASDAQ:VYNE)CurrentInstitutional OwnershipPercentage83.78%Number ofInstitutional Buyers(last 12 months)18TotalInstitutional Inflows(last 12 months)$5.58MNumber ofInstitutional Sellers(last 12 months)6TotalInstitutional Outflows(last 12 months)$641.69K Get VYNE Insider Trade Alerts Want to know when executives and insiders are buying or selling VYNE Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Skip Chart & View Institutional Buying and Selling Data VYNE Institutional Buying and Selling by Quarter VYNE Therapeutics Major Shareholders & Ownership History ExportReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails5/19/2026 Anson Funds Management LP1,243,106$743K0.1%-2.5%3.731% 5/18/2026 ADAR1 Capital Management LLC1,063,899$636K0.0%+319.2%3.193% 5/15/2026 Rangeley Capital LLC118,064$71K0.1%+18.1%0.354% 2/18/2026 KVP Capital Advisors LP500,551$290K0.3%N/A1.504% 2/18/2026 XTX Topco Ltd79,040$46K0.0%N/A0.237% 2/18/2026 Ikarian Capital LLC264,912$154K0.0%-8.7%0.796% 2/18/2026 Boothbay Fund Management LLC81,371$47K0.0%-23.6%0.244% 2/17/2026 ADAR1 Capital Management LLC253,791$147K0.0%N/A0.762% 2/17/2026 Anson Funds Management LP1,274,386$739K0.1%N/A3.828% 2/13/2026 Nantahala Capital Management LLC1,000,000$580K0.0%N/A3.004% Get the Latest News and Ratings for VYNE and Related StocksEnter your email address below to receive the latest news and analysts' ratings for VYNE Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 2/12/2026 Jane Street Group LLC72,356$42K0.0%-50.8%0.217% 2/11/2026 T3 Companies LLC945,000$548K0.7%N/A2.839% 2/9/2026 Geode Capital Management LLC225,152$131K0.0%+64.2%0.676% 11/17/2025 Acorn Capital Advisors LLC586,572$199K0.1%-20.4%1.762% 11/17/2025 Baker BROS. Advisors LP851,353$285K0.0%N/A2.557% 11/14/2025 Shay Capital LLC492,577$165K0.0%N/A1.934% 11/14/2025 Two Sigma Investments LP220,788$74K0.0%N/A0.867% 8/15/2025 Exome Asset Management LLC208,970$345K0.2%-54.8%1.374% 8/15/2025 Boothbay Fund Management LLC106,459$176K0.0%N/A0.700% 8/15/2025 Acorn Capital Advisors LLC736,572$1.22M0.8%-6.3%4.843% 8/15/2025 Adage Capital Partners GP L.L.C.644,134$1.06M0.0%+87.2%4.235% 8/14/2025 Jane Street Group LLC124,822$206K0.0%N/A0.821% 8/14/2025 TFG Asset Management GP Ltd115,384$190K0.0%N/A0.759% 8/14/2025 Velan Capital Investment Management LP30,000$50K0.0%N/A0.197% 8/13/2025 Kennedy Capital Management LLC570,740$942K0.0%N/A3.752% 8/11/2025 Patient Square Capital LP317,033$523K0.2%+23.3%2.084% 5/19/2025Acorn Capital Advisors LLC785,938$1.24M0.8%+72.0%5.167% 5/16/2025Exome Asset Management LLC462,801$731K0.6%+30.9%3.043% 5/16/2025Parkman Healthcare Partners LLC217,978$344K0.0%+42.5%1.433% 5/16/2025Adage Capital Partners GP L.L.C.344,134$544K0.0%+123.3%2.263% 5/16/2025ADAR1 Capital Management LLC70,419$111K0.0%N/A0.463% 5/15/2025DAFNA Capital Management LLC636,103$1.01M0.3%N/A4.182% 5/12/2025Virtu Financial LLC19,574$31K0.0%N/A0.129% 5/8/2025XTX Topco Ltd33,052$52K0.0%+57.3%0.217% 2/17/2025Parkman Healthcare Partners LLC152,973$512K0.1%-24.6%1.037% 2/17/2025OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC245,800$823K0.1%N/A1.666% 2/17/2025Bridgeway Capital Management LLC36,958$124K0.0%N/A0.251% 2/17/2025Acorn Capital Advisors LLC456,970$1.53M0.8%N/A3.098% 2/14/2025Jane Street Group LLC20,286$68K0.0%N/A0.138% 2/14/2025Schonfeld Strategic Advisors LLC176,658$592K0.0%+4.8%1.198% A 17-year investing experiment investigated in Dublin (Ad)Porter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experiment called Project Prophet - and documented everything on film. Rooted in the laws of physics, this quantitative approach challenges conventional wealth-building wisdom. With 17 years of verified data behind it, Porter calls it unlike anything he has seen in nearly 30 years in the business.Watch the full investigation and decide for yourself2/14/2025Northern Trust Corp23,971$80K0.0%-35.7%0.163% 2/14/2025Adage Capital Partners GP L.L.C.154,134$516K0.0%N/A1.045% 2/13/2025XTX Topco Ltd21,018$70K0.0%N/A0.142% 2/13/2025Renaissance Technologies LLC24,943$84K0.0%-71.2%0.169% 11/15/2024Parkman Healthcare Partners LLC202,973$382K0.0%-41.2%1.376% 10/30/2024AlphaCentric Advisors LLC268,485$505K0.4%-13.5%1.820% 8/15/2024Lynx1 Capital Management LP16,194$32K0.0%N/A0.111% 8/9/2024Renaissance Technologies LLC63,111$124K0.0%-21.7%0.434% 7/26/2024AlphaCentric Advisors LLC310,500$612K0.5%-30.2%2.137% 5/20/2024Virtu Financial LLC16,199$50K0.0%N/A0.112% 2/20/2024Eventide Asset Management LLC1,394,336$3.25M0.1%N/A9.988% 2/15/2024Parkman Healthcare Partners LLC696,470$1.62M0.2%N/A4.990% 5/15/2023DSC Advisors L.P.115,000$354K0.3%-92.7%3.523% 5/10/2023Staley Capital Advisers Inc.23,472$72K0.0%-62.4%0.720% 10/7/2022Mackenzie Financial Corp134,920$30K0.0%+106.8%0.233% 4/25/2022Bailard Inc.139,381$91K0.0%N/A0.248% 2/15/2022DSC Advisors L.P.2,551,000$2.60M2.0%+131.9%4.767% 2/14/2022Perceptive Advisors LLC2,178,022$2.22M0.0%-6.5%4.070% 2/14/2022GSA Capital Partners LLP217,747$222K0.0%+135.7%0.407% VYNE Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of VYNE shares? During the previous two years, 31 institutional investors and hedge funds held shares of VYNE Therapeutics. The most heavily invested institutionals were Adage Capital Partners GP L.L.C. ($1.06M), DAFNA Capital Management LLC ($1.01M), Kennedy Capital Management LLC ($942K), OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC ($823K), Anson Funds Management LP ($743K), ADAR1 Capital Management LLC ($636K), and Schonfeld Strategic Advisors LLC ($592K).Learn more on VYNE Therapeutics' institutional investors. What percentage of VYNE Therapeutics' stock is owned by institutional investors? 83.78% of VYNE Therapeutics' stock is owned by institutional investors. Learn more on VYNE's institutional investor holdings. Which institutional investors have been buying VYNE Therapeutics' stock? Of the 27 institutional investors that purchased VYNE Therapeutics' stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: Anson Funds Management LP ($1.27M), ADAR1 Capital Management LLC ($1.13M), Nantahala Capital Management LLC ($1M), T3 Companies LLC ($945K), Baker BROS. Advisors LP ($851.35K), Acorn Capital Advisors LLC ($785.94K), and Adage Capital Partners GP L.L.C. ($644.13K). How much institutional buying is happening at VYNE Therapeutics? Institutional investors have bought a total of 7,841,093 shares in the last 24 months. This purchase volume represents approximately $5.58M in transactions. Which of VYNE Therapeutics' major shareholders have been selling company stock? The following institutional investors have sold VYNE Therapeutics stock in the last 24 months: Exome Asset Management LLC ($253.83K), Acorn Capital Advisors LLC ($199.37K), Jane Street Group LLC ($74.76K), Anson Funds Management LP ($31.28K), Boothbay Fund Management LLC ($25.09K), and Ikarian Capital LLC ($25.09K). How much institutional selling is happening at VYNE Therapeutics? Institutional investors have sold a total of 609,417 shares in the last 24 months. This volume of shares sold represents approximately $641.69K in transactions. Related Companies ICCC Institutional Ownership CLNN Institutional Ownership CUE Institutional Ownership ATRA Institutional Ownership EDSA Institutional Ownership BHST Institutional Ownership CTOR Institutional Ownership BTMD Institutional Ownership RLYB Institutional Ownership MCRB Institutional Ownership This page (NASDAQ:VYNE) was last updated on 5/22/2026 by MarketBeat.com Staff. From Our PartnersHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredThe SpaceX supplier that shipped 5 billion chips to StarlinkWhen Nvidia surged 770%, its data center cooling supplier Vertiv climbed 1,700%. When Apple ran 2,000%, suppli...Weiss Ratings | SponsoredGoldman Sachs just told you what to buy (most people missed it)Goldman Sachs just revealed that 40% of AI data centers will be crippled by electricity shortages by 2027 - no...Behind the Markets | Sponsored"Computers are about to become obsolete" - George Gilder. Here’s why.George Gilder predicted the iPhone 16 years early, called Netflix a decade before it dominated streaming, and ...Eagle Publishing | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredTo Avoid 67 Million Blackouts, Trump Signs Emergency Backing of New Energy TechPresident Trump has used emergency executive powers to back a new energy technology described as 326 times mor...Altimetry | SponsoredElon’s Biggest Launch Ever: 15x Bigger Than SpaceXThe Man Who Called Nvidia Before It Soared 1,000% Issues New Elon Musk BUY Alert Luke Lango was ranked Amer...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding VYNE Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share VYNE Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
